Tagrisso (Osimertinib) 80mg*30 | AstraZeneca China NMPA | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

Share
Product description

Generic Information: Tagrisso (Osimertinib) 80mg — China-Mainland

This is the China-Mainland presentation of Tagrisso, AstraZeneca's originator osimertinib, supplied as 80 mg film-coated tablets in a 30-tablet box. Osimertinib was approved by China's NMPA and has since been included in the national medical insurance drug list, where it is reimbursed as a Category B (乙类) medicine for EGFR-mutant non-small cell lung cancer. That reimbursement status makes the China version one of the most affordable originator osimertinib presentations globally for eligible patients.

The Chinese-language label is "泰瑞沙" (Tàiruìshā), and the pack carries NMPA approval details alongside AstraZeneca branding. For cross-border buyers, the China version is notable because its reimbursed price is substantially below Western list prices, which is the core value proposition of sourcing from China.

What Is Tagrisso Used For?

Tagrisso is indicated for EGFR mutation-positive NSCLC: first-line treatment of advanced disease with exon 19 deletions or L858R mutations, adjuvant therapy after surgery for early-stage EGFR-mutant NSCLC, and T790M-positive disease after prior EGFR-TKI therapy. Its ability to cross the blood-brain barrier makes it particularly useful when central nervous system metastases are present.

How Does Tagrisso Work?

Osimertinib irreversibly inhibits mutated EGFR, including the T790M resistance mutation, while sparing wild-type EGFR at clinical doses. This mutant-selective mechanism is why it is effective both as an initial therapy and after resistance to first- and second-generation EGFR inhibitors, and why its skin and gut toxicity is generally milder.

Indications

  • First-line advanced EGFR-mutant NSCLC (exon 19 del / L858R).
  • Adjuvant therapy after complete resection of early-stage EGFR-mutant NSCLC.
  • T790M-positive NSCLC after progression on prior EGFR-TKI therapy.

Dosage and Administration

Take one 80 mg tablet once daily, with or without food, swallowed whole. If a dose is missed by more than 12 hours, skip it and resume the next day. For swallowing difficulty, the tablet can be dispersed in 50 mL of non-carbonated water. A reduced dose of 40 mg daily may be used to manage adverse reactions.

Side Effects

Frequent adverse reactions are diarrhoea, rash, dry skin, nail toxicity, stomatitis and fatigue. Serious risks include interstitial lung disease, QT prolongation and reduced cardiac function; these require regular monitoring. New or worsening cough, breathlessness or palpitations should be reported to the treating physician immediately.

Storage

Store below 30°C, in the original package, away from moisture and out of children's reach. Use before the printed expiry date.

Why Choose the China Version of Tagrisso?

The China-Mainland Tagrisso stands out for its price: because it is nationally reimbursed, its effective cost is far below the list price of the same medicine in the United States and Europe — roughly a small fraction of the US list price, and meaningfully cheaper than in Japan and several European markets. For institutions and patients able to source through China, this is one of the most economical ways to access originator osimertinib without switching to a generic. GLT documents each batch and guides buyers through import requirements.

How to Order Tagrisso (China) from GLT

To order the China-Mainland Tagrisso 80 mg (30 tablets), message GLT on WhatsApp at +86 15234153837 or email [email protected]. State your quantity, destination and whether the order is personal or institutional. We confirm the current reimbursed China price, batch origin and required export documentation before dispatch.

FAQ

Is Tagrisso reimbursed in China? Yes, Tagrisso (osimertinib) is included in China's national medical insurance list as a Category B medicine for EGFR-mutant NSCLC.

Why is China Tagrisso cheaper? China's national reimbursement negotiation has brought the price of Tagrisso well below Western list prices, making the China presentation an economical originator option.

Can I buy China Tagrisso from outside China? GLT can help international buyers source the China presentation with proper export documentation; contact us on WhatsApp or email.

Related Oncology Products

Barinib (Baricitinib) 2mg | Generic JAK1/JAK2 Inhibitor | Drug International Limited | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Drug International Limited (Bangladesh) — an affordable alternative to Olumiant...

XinKePing 欣可平 (Avatrombopag) 20mg*10 Tablets | Nanjing Hencer China | GLT

XinKePing — API-plus-tablet integrated avatrombopag from Nanjing Hencer Pharmaceutical (Jemcare group), China Mainland

Tirzema (Tirzepatide) 2.5/5/7.5mg/0.5mL Single-Dose Pen | Incepta Bangladesh | GLT

Tirzema — Incepta Pharmaceuticals tirzepatide single-dose pen, three official strengths (2.5/5/7.5mg/0.5mL) for T2DM and weight...

KeZeRui 科瑞泽 (Avatrombopag) 20mg*10 Tablets | Sichuan Kelun China | GLT

KeZeRui — national-procurement avatrombopag from Sichuan Kelun Pharmaceutical, China's integrated API + tablet maker

SPINRAZA (Nusinersen) 12mg/5mL | Buy from China | SMA Therapy | GLT

Biogen's first-in-class antisense oligonucleotide for SMA, NMPA-approved and nationally reimbursed in China — buy from...

Olumiant (Baricitinib) 2mg/4mg Tablets | JAK1/JAK2 Inhibitor | Eli Lilly USA | GLT

Eli Lilly's selective JAK1/JAK2 inhibitor for rheumatoid arthritis, atopic dermatitis and severe alopecia areata.

Mounjaro KwikPen (Tirzepatide) 10–60mg/2.4mL Multi-Dose | Eli Lilly USA | GLT

Mounjaro KwikPen — Eli Lilly single-patient multi-dose pen, six US strengths (10–60mg/2.4mL, 4 doses each)...

Barinat (Baricitinib) 4mg | Generic JAK1/JAK2 Inhibitor | Natco Pharma Limited | GLT

Generic baricitinib (JAK1/JAK2 inhibitor) by Natco Pharma Limited (India) — an affordable alternative to Olumiant...